CA3242755A1 - Deuterated organic compounds and uses thereof - Google Patents

Deuterated organic compounds and uses thereof

Info

Publication number
CA3242755A1
CA3242755A1 CA3242755A CA3242755A CA3242755A1 CA 3242755 A1 CA3242755 A1 CA 3242755A1 CA 3242755 A CA3242755 A CA 3242755A CA 3242755 A CA3242755 A CA 3242755A CA 3242755 A1 CA3242755 A1 CA 3242755A1
Authority
CA
Canada
Prior art keywords
deteriorative
organic compounds
compounds
formula
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3242755A
Other languages
English (en)
French (fr)
Inventor
Krishna VADODARIA
Kimberly Vanover
Jordi SERRATS
Vikram SUDARSAN
David Garvey
Original Assignee
Engrail Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engrail Therapeutics Inc filed Critical Engrail Therapeutics Inc
Publication of CA3242755A1 publication Critical patent/CA3242755A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3242755A 2022-01-03 2023-01-03 Deuterated organic compounds and uses thereof Pending CA3242755A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202263296137P 2022-01-03 2022-01-03
US63/296,137 2022-01-03
US202263314466P 2022-02-27 2022-02-27
US63/314,466 2022-02-27
US202263345002P 2022-05-23 2022-05-23
US63/345,002 2022-05-23
US202263394565P 2022-08-02 2022-08-02
US63/394,565 2022-08-02
US202263384988P 2022-11-25 2022-11-25
US63/384,988 2022-11-25
PCT/US2023/010055 WO2023130119A1 (en) 2022-01-03 2023-01-03 Deuterated organic compounds and uses thereof

Publications (1)

Publication Number Publication Date
CA3242755A1 true CA3242755A1 (en) 2023-07-06

Family

ID=87000385

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3242755A Pending CA3242755A1 (en) 2022-01-03 2023-01-03 Deuterated organic compounds and uses thereof

Country Status (10)

Country Link
US (1) US12606523B2 (https=)
EP (1) EP4460292A4 (https=)
JP (1) JP2025501411A (https=)
KR (1) KR20240132477A (https=)
AU (1) AU2023204433A1 (https=)
CA (1) CA3242755A1 (https=)
IL (1) IL313999A (https=)
MX (1) MX2024008371A (https=)
TW (1) TW202333671A (https=)
WO (1) WO2023130119A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202517609A (zh) 2023-07-02 2025-05-01 美商英格瑞治療公司 氘化有機化合物及其用途(二)
WO2026011157A1 (en) 2024-07-05 2026-01-08 Engrail Therapeutics, Inc. Crystalline forms

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4197243A (en) * 1975-04-02 1980-04-08 Yamanouchi Pharmaceutical Co., Ltd. N-1-Benzyl-3-pyrrolidinyl-4-dimethylamino benzamide derivatives
US4210660A (en) 1978-12-20 1980-07-01 Yamanouchi Pharmaceutical Co., Ltd. Benzamide derivatives
TW212139B (https=) 1991-04-15 1993-09-01 Yamanouchi Pharma Co Ltd
SK281042B6 (sk) 1992-09-18 2000-11-07 Yamanouchi Pharmaceutical Co., Ltd Prípravok hydrogélového typu s ustáleným uvoľňovaním
EP0667867A1 (en) 1992-11-05 1995-08-23 Smithkline Beecham Plc Piperidine derivatives as 5-ht4 receptor antagonists
US6872405B2 (en) 2001-05-10 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. Quick-disintegrating tablet in buccal cavity and manufacturing method thereof
KR102373288B1 (ko) 2013-12-03 2022-03-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
CN104744333A (zh) 2013-12-26 2015-07-01 张云 一种奈莫必利的生产方法
US20190343827A1 (en) 2018-05-08 2019-11-14 Izumi Technology, Llc Deuterated analogs of tariquidar
MX2021010198A (es) 2019-02-27 2021-09-21 Univ California Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales.
US20210017160A1 (en) 2019-07-16 2021-01-21 Cyclerion Therapeutics, Inc. DEUTERATED sGC STIMULATORS
TW202340145A (zh) 2022-01-03 2023-10-16 美商恩格瑞爾療法公司 氘化有機化合物及其用途
TW202517609A (zh) 2023-07-02 2025-05-01 美商英格瑞治療公司 氘化有機化合物及其用途(二)

Also Published As

Publication number Publication date
WO2023130119A1 (en) 2023-07-06
US20250011280A1 (en) 2025-01-09
KR20240132477A (ko) 2024-09-03
EP4460292A1 (en) 2024-11-13
MX2024008371A (es) 2024-12-06
JP2025501411A (ja) 2025-01-17
IL313999A (en) 2024-08-01
TW202333671A (zh) 2023-09-01
EP4460292A4 (en) 2025-07-16
US12606523B2 (en) 2026-04-21
AU2023204433A1 (en) 2024-07-18

Similar Documents

Publication Publication Date Title
BR112022019991A2 (pt) Compostos, composição farmacêutica compreendendo o mesmo, e usos dos mesmos
EA201892838A1 (ru) Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их
CA3242755A1 (en) Deuterated organic compounds and uses thereof
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
EA201891622A1 (ru) Новые производные аммония, способ их получения и фармацевтические композиции, содержащие их
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
GEAP202215303A (en) Chromane monobactam compounds for the treatment of bacterial infections
JOP20220085A1 (ar) مركبات أريل ميثيلين حلقية غير متجانسة على هيئة حاصرات قناة بوتاسيوم Kv1.3 بجين شاكر
MY167777A (en) A pharmaceutical composition comprising electrohydrodynamically obtained fibres, the composition having improved residence time on the application site
DE602005008065D1 (de) Von phosphatidylinosit-(pi-)3-kinase und deren verwendung bei der behandlung von krebs
BRPI0612125A2 (pt) compostos da fórmula (i), processo para a fabricação destes, composto da fórmula iiia, composições farmacêuticas, método para o tratamento e/ou profilaxia de doenças associadas à modulação dos receptores cb1 e uso de compostos
DE602005023755D1 (de) Indolonderivate, verfahren zu deren herstellung und deren anwendungen
SA522431304B1 (ar) عمليات تحضير اللاسميديتان وملح الأسيتات منه
EP3694330A4 (en) INDAZOLYL-SPIRO [2.2] PENTANCARBONITRIL DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES
WO2025010259A3 (en) Deuterated organic compounds and uses thereof
EP4599892A3 (en) Boronic acid derivatives and therapeutic uses thereof
WO2020024017A9 (en) Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
MX2024008372A (es) Compuestos organicos deuterados y usos de los mismos
BR112018067918A2 (pt) formulações livres de solvente de substâncias ativas com baixo ponto de fusão
BRPI0508177A (pt) composto, processo para a produção do composto, composição farmacêutica, uso do composto método para o tratamento de uma doença e produto de combinação
MA41174B1 (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
BR112023022917A2 (pt) Moduladores de trex1
BR112017015474A2 (pt) inibidores de bace1

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: IPC ASSIGNED

Effective date: 20240702

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: IPC REMOVED

Effective date: 20240702

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W005 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: FIRST IPC ASSIGNED

Effective date: 20240702

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20240703

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240703

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241217

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241217

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241217